High Prevalence of Esophageal Acid Exposure in Very Low Birth Weight Infants Presenting or Not Bronchopulmonary Dysplasia: A Prospective Cross-Sectional Study
Abstract
Background: A high frequency of treatment for gastroesophageal reflux disease is observed in neonates with Bronchopulmonary Dysplasia (BPD). The association between these illnesses is controversial. Objective: To determine the prevalence of reflux index ≥ 10%, in very low birth weight infants, presenting or not BPD, using esophageal pH monitoring.
Methods: A prospective cross-sectional study was conducted. Thirty-five newborns presenting BPD and 15 newborns not presenting BPD underwent distal esophageal pH monitoring during their stay in a university hospital neonatal unit. The frequency of symptoms and gastroesophageal reflux treatment was studied in both groups.
Results: The prevalence of reflux index ≥ 10% did not differ between groups presenting (65.7%) and not presenting BPD (93.3%); p=0.075. Symptoms attributable to gastroesophageal reflux occurred in 91.4% of newborns presenting BPD and in 73.3% of the group not presenting BPD. Antireflux treatment was introduced to 80% of the subjects presenting BPD and to 20% of patients who were not presenting BPD; (p<0.001).
Conclusions:There is a high prevalence of increased esophageal mucosal exposure to acid in very low birth weight infants presenting or not BDP. The symptoms attributable to gastroesophageal reflux are frequent in both groups; however, in very low birth weight infants, not presenting BPD, a clinical progression complicated by gastroesophageal reflux is less frequent. Nevertheless, BPD is associated with a…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.